Aurinia Pharmaceuticals Inc. (AUPH)
Largest Insider Buys in Sector
AUPH Stock Price History Chart
AUPH Stock Performance
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Insider Activity of Aurinia Pharmaceuticals Inc.
Over the last 12 months, insiders at Aurinia Pharmaceuticals Inc. have bought $0 and sold $2.03M worth of Aurinia Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at Aurinia Pharmaceuticals Inc. have bought $424,299 and sold $15.78M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 20,000 shares for transaction amount of $178,284 was made by MILNE GEORGE M JR (director) on 2023‑03‑02.
List of Insider Buy and Sell Transactions, Aurinia Pharmaceuticals Inc.
| 2024-08-06 | Sale | Chief Commercial Officer | 18,249 0.0121% | $5.31 | $96,902 | +24.56% | ||
| 2024-05-21 | Sale | director | 4,946 0.0036% | $5.74 | $28,390 | +17.32% | ||
| 2024-05-21 | Sale | director | 5,252 0.0038% | $5.74 | $30,146 | +17.32% | ||
| 2024-05-21 | Sale | director | 5,630 0.004% | $5.74 | $32,316 | +17.32% | ||
| 2024-05-21 | Sale | director | 520 0.0004% | $5.74 | $2,985 | +17.32% | ||
| 2024-05-21 | Sale | director | 5,610 0.004% | $5.74 | $32,201 | +17.32% | ||
| 2024-03-06 | Sale | Chief Executive Officer | 126,981 0.0894% | $5.60 | $711,094 | -1.27% | ||
| 2024-03-06 | Sale | EVP, Ops & Strategy | 40,665 0.0282% | $5.51 | $224,064 | -1.27% | ||
| 2024-03-06 | Sale | Chief Financial Officer | 34,811 0.0245% | $5.60 | $194,942 | -1.27% | ||
| 2024-03-06 | Sale | Chief Commercial Officer | 17,777 0.0125% | $5.60 | $99,551 | -1.27% | ||
| 2024-03-06 | Sale | EVP, General Counsel | 57,745 0.0407% | $5.60 | $323,372 | -1.27% | ||
| 2024-02-27 | Sale | EVP, Research and Development | 4,930 0.0034% | $6.10 | $30,073 | -8.47% | ||
| 2024-02-20 | Sale | Chief Commercial Officer | 15,867 0.0108% | $5.48 | $86,951 | -1.07% | ||
| 2024-02-20 | Sale | EVP, Research and Development | 25,146 0.0171% | $5.48 | $137,800 | -1.07% | ||
| 2023-05-23 | Sale | director | 8,733 0.0061% | $11.26 | $98,334 | -27.72% | ||
| 2023-05-23 | Sale | director | 4,650 0.0032% | $11.26 | $52,359 | -27.72% | ||
| 2023-05-23 | Sale | director | 4,818 0.0034% | $11.26 | $54,251 | -27.72% | ||
| 2023-05-23 | Sale | director | 4,815 0.0034% | $11.26 | $54,217 | -27.72% | ||
| 2023-05-19 | Sale | director | 272 0.0002% | $10.58 | $2,878 | -22.65% | ||
| 2023-03-02 | Sale | Chief Executive Officer | 33,047 0.0228% | $8.78 | $290,153 | +2.52% |
Insider Historical Profitability
| Greenleaf Peter | Chief Executive Officer | 1522114 1.0645% | $7.49 | 1 | 3 | +37.58% |
| Donley Matthew Maxwell | EVP, Ops & Strategy | 584072 0.4085% | $7.49 | 2 | 2 | +67.17% |
| Miller Joseph M | Chief Financial Officer | 495928 0.3468% | $7.49 | 1 | 3 | +37.58% |
| Habig Scott Michael | Chief Commercial Officer | 456338 0.3191% | $7.49 | 1 | 3 | +81.51% |
| Robertson Stephen P. | EVP, General Counsel | 443824 0.3104% | $7.49 | 1 | 2 | <0.0001% |
Institutional Investor Ownership
| Armistice Capital Llc | $61.42M | 8.57 | 12.26M | +28.57% | +$13.65M | 0.2 | |
| BlackRock | $43.4M | 6.06 | 8.66M | -2.89% | -$1.29M | <0.01 | |
| Nea Management Company Llc | $19.89M | 2.78 | 3.97M | 0% | +$0 | 0.09 | |
| State Street | $13.88M | 1.94 | 2.77M | +2.46% | +$333,074.83 | <0.01 | |
| Goldman Sachs | $10.78M | 1.51 | 2.15M | +5.06% | +$519,527.00 | <0.01 |